Institutional members access full text with Ovid®

Share this article on:

Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM

Marchegiani, Giovanni MD*; Andrianello, Stefano MD*; Malleo, Giuseppe MD*; De Gregorio, Lucia MD; Scarpa, Aldo MD; Mino-Kenudson, Mari MD§; Maggino, Laura MD*; Ferrone, Cristina R. MD; Lillemoe, Keith D. MD; Bassi, Claudio MD*; Castillo, Carlos Fernàndez-del MD; Salvia, Roberto MD*

doi: 10.1097/SLA.0000000000001837
Original Articles

Objective: To explore the role of pancreatic ductal adenocarcinoma (PDAC) size on surgical and survival outcomes.

Background: Tumor size is a prognostic factor for the majority of solid cancers, but the role for PDAC in predicting survival is not well delineated affecting the reliability of tumor node metastasis system classification.

Methods: Between 1998 and 2012, 1507 patients with PDAC underwent resection at University of Verona Hospital and the Massachusetts General Hospital. All data were collected prospectively. Tumor size has been measured both at imaging and gross pathology.

Results: Among the tumors measured, 21.5% were <20 mm and 78.5% >20 mm. Larger tumors were associated with higher Ca19.9, T3-T4 and N1, higher grade, perineural invasion, R1 resections, more positive lymph nodes, and higher lymph node ratios (P < 0.05). Tumours <20 mm showed a better prognosis (33 vs 23 months; P < 0.01), but worse surgical results with higher pancreatic fistula (21.1% vs 14.6%; P < 0.01) and mortality rates (1.5% vs 0.3%; P = 0.04). PDAC size was associated with worse prognosis (hazard ratio 1.26, P = 0.02), together with Ca19.9, grading, and N1. When measured at imaging, tumor size was underestimated (median 23 vs 30 mm; P < 0.01) and did not influence prognosis

Conclusions: PDAC size >20 mm, measured at gross pathology, correlates with surgical outcomes and is an independent predictor of poor prognosis. Given that imaging underestimates size by about 20%, perhaps tumors that measure >20 mm at imaging should be considered for neoadjuvant treatment regardless of resectability.

*General and Pancreatic Surgery Department, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy

General Surgery Department, Massachusetts General Hospital – Harvard Medical School, Boston, MA

Department of Pathology, ARC-Net Research Centre, University of Verona Hospital Trust, Verona, Italy

§Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Reprints: Roberto Salvia, MD, PhD, Associate Professor of Surgery, University of Verona Hospital Trust, P.le Scuro 10, 37134 Verona, Italy. E-mail: roberto.salvia@univr.it.

Funding: This work was supported by: Associazione Italiana Ricerca Cancro [AIRC n.12182 and n.17132]; Italian Ministry of Health [FIMP-CUP_J33G13000210001]; FP7 European Community Grant Cam-Pac [n. 602783].

Disclosure: The funding agencies had no role in the collection, analysis and interpretation of data and in the writing of the manuscript.

The authors state that there is no conflict of interest.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.